The DOI matches its Crossref record; 312 of the 314 references it cites were found in a registry or an index; none of the 132 sources its claims cite is checked for support yet.
Mitochondrial Approaches for Neuroprotection
Open accessAbstract
A large body of evidence from postmortem brain tissue and genetic analysis in humans and biochemical and pathological studies in animal models (transgenic and toxin) of neurodegeneration suggest that mitochondrial dysfunction is a common pathological mechanism. Mitochondrial dysfunction from oxidative stress, mitochondrial DNA deletions, pathological mutations, altered mitochondrial morphology, and interaction of pathogenic proteins with mitochondria leads to neuronal demise. Therefore, therapeutic approaches targeting mitochondrial dysfunction and oxidative damage hold great promise in neurodegenerative diseases. This review discusses the potential therapeutic efficacy of creatine, coenzyme Q10, idebenone, synthetic triterpenoids, and mitochondrial targeted antioxidants (MitoQ) and peptides (SS‐31) in in vitro studies and in animal models of Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Alzheimer's disease. We have also reviewed the current status of clinical trials of creatine, coenzyme Q10, idebenone, and MitoQ in neurodegenerative disorders. Further, we discuss newly identified therapeutic targets, including peroxisome proliferator‐activated receptor‐γ‐coactivator and sirtuins, which provide promise for future therapeutic developments in neurodegenerative disorders.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that mitochondrial dysfunction and oxidative damage are common pathological mechanisms in Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis. It evaluates mitochondria-targeted neuroprotective agents—including creatine, coenzyme Q10, idebenone, MitoQ, SS-31, and synthetic triterpenoids—and highlights PGC-1α and sirtuins as emerging therapeutic targets.
Key findings
- Mitochondrial dysfunction is implicated across neurodegenerative diseases: complex-I inhibition by MPTP/rotenone in PD models; reduced complexes II–III and aconitase in HD; impaired TCA enzymes and respiratory complexes I, III, and IV in AD; and mutant SOD1-associated mitochondrial defects in ALS.
- Creatine showed neuroprotection in multiple models, including MPTP-treated mice, G93A ALS mice, and R6/2 and N-171-82Q HD mice. In early PD, a phase II trial of creatine 10 g/day plus minocycline reported tolerability of 91% for creatine versus 77% for minocycline, and UPDRS progression slowed by almost 50% at 1 year compared with DATATOP controls; an NIH phase III trial planned to randomize 1720 participants to 10 g creatine or placebo. In HD, creatine 8 g/day for 16 weeks in 64 subjects was safe, bioavailable to brain, and decreased serum 8-hydroxy-2-deoxyguanosine.
- CoQ10 at 360 mg/day reduced occipital cortex lactate concentrations by 37% in 18 HD patients. In the CARE-HD trial of 340 patients, CoQ10 600 mg/day produced a 14% decrease in disease progression over 30 months, while remacemide showed no efficacy. A phase II early-PD trial using 300, 600, or 1,200 mg/day for 16 months found a statistically significant dose-dependent reduction in UPDRS score; high doses up to 3,600 mg/day were safe, though plasma CoQ10 plateaued at 2,400 mg/day.
- Mitochondrial-targeted agents showed preclinical promise: MitoQ entered a phase II PD trial; SS-31 at 5 mg/kg daily intraperitoneally from 30 days of age improved survival and motor performance in G93A ALS mice; CDDO-MA reduced MPTP and 3-NP toxicity; and PGC-1α and sirtuin/resveratrol pathways were protective in models of neurodegeneration.
Methods
- Design: narrative review; no systematic review, meta-analysis, or formal search methodology is stated.
- Data/sample: evidence from post-mortem human tissue, genetic analyses, in vitro cell models, transgenic and toxin animal models, and clinical trials in PD, HD, AD, and ALS.
- Analysis: qualitative synthesis of preclinical and clinical findings for mitochondrial-targeted neuroprotective agents and emerging targets including PGC-1α and sirtuins.
Limitations
- The paper states no explicit limitations.
- Evident from the text: as a narrative review, it lacks systematic search criteria, inclusion/exclusion criteria, and quantitative synthesis.
- Evident from the text: several cited findings are unpublished (e.g., Chaturvedi et al., Kipiani et al., Yang et al., Kiaei et al.), and clinical results for idebenone are described as controversial, with one large trial showing no benefit.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
93 Not checked yet · 24 Own interpretation · 2 Own result
In the paper
“We observed G11778A mtDNA point mutation in a subunit of mitochondrial complex-I in a family with parkinsonism and multisystem degeneration19.”
§ Mitochondrial approaches for neuroprotection > Mitochondrial dysfunction in Parkinson's disease (PD)
What the sources say
- Not checked yetcites [19] Simon DK 1999 Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation Neurology 53 1787 93 10563629 source
plaincorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“We also identified high levels of somatic mtDNA point mutations in elderly PD patients20.”
§ Mitochondrial approaches for neuroprotection > Mitochondrial dysfunction in Parkinson's disease (PD)
What the sources say
- Not checked yetcites [20] Simon DK 2004 Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease Neurobiol Aging 25 71 81 14675733 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“We found neuroprotective effects against DA depletion, loss of TH-IR neurons in the SN and the development of α–synuclein aggregates.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [147] Cleren C 2007 Therapeutic effects of coenzyme Q(10) (Q(10)) and reduced CoQ(10) in the MPTP model of Parkinsonism J Neurochem 17973981
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Recently, we found that a combination of creatine and CoQ10 exerts synergistic neuroprotective effects in the MPTP model of PD (Yang et al., unpublished findings).”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites Yang et al., unpublished findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“We demonstrated CoQ10 provided significant protection against MPTP induced dopamine depletion and loss of TH-IR neurons in aged mice146.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [146] Beal MF 1998 Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice Brain Res 783 109 14 9479058 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“We found neuroprotective effects against DA depletion, loss of TH-IR neurons in the SN and the development of α–synuclein aggregates.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [147] Cleren C 2007 Therapeutic effects of coenzyme Q(10) (Q(10)) and reduced CoQ(10) in the MPTP model of Parkinsonism J Neurochem 17973981
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“We found neuroprotective effects against DA depletion, loss of TH-IR neurons in the SN and the development of α–synuclein aggregates.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [147] Cleren C 2007 Therapeutic effects of coenzyme Q(10) (Q(10)) and reduced CoQ(10) in the MPTP model of Parkinsonism J Neurochem 17973981
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“We observed that CoQ10 treatment produced a 37% reduction in occipital cortex lactate concentrations, which was reversed following withdrawal of therapy39.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [39] Koroshetz WJ 1997 Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 Ann Neurol 41 160 5 9029064 source
plaindirectn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“More recently, we found that dietary administration of either of two formulations of CoQ10 resulted in significant protection in a chronic MPTP model induced by the administration of MPTP by Alzet pump for 1 month147.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [147] Cleren C 2007 Therapeutic effects of coenzyme Q(10) (Q(10)) and reduced CoQ(10) in the MPTP model of Parkinsonism J Neurochem 17973981
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“We found SS-31 mediated significant neuroprotection against cell death induced by hydrogen peroxide in SOD1 neuronal cells.”
§ Mitochondrial approaches for neuroprotection > Mitochondrial targeted antioxidants/peptides
What the sources say
- Not checked yetcites [180] Petri S 2006 Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis J Neurochem 98 1141 8 16895581 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 4
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed significantly reduced cellular respiration and COX activity in myoblasts from HD patients, and these defects were exacerbated in chronic energy deprivation conditions (Chaturvedi et. al., unpublished findings).”
§ Mitochondrial approaches for neuroprotection > Mitochondrial dysfunction in Huntington's disease (HD)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“We found that oral administration of creatine at a dose of 8 g/day for 16 weeks is well tolerated, safe and bioavailable to the brain, and it decreased serum 8-hydroxy-2-deoxyguanosine levels, a marker for oxidative stress.”
§ Mitochondrial approaches for neuroprotection > Creatine
What the sources say
- Not checked yetcites [134] Hersch SM 2006 Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG Neurology 66 250 2 16434666 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recently, we found that CoQ10 treatment decreases brain oxidative stress, Aβ42 levels, β-amyloid plaque area and number, and improves cognitive performance in Tg19959 mice, a transgenic mouse model of AD (Kipiani et al., unpublished findings).”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites Kipiani et al., unpublished findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“We found that creatine significantly improves survival, improves motor performance, slows the development of brain atrophy, increases brain ATP levels, delays atrophy of striatal neurons and the formation of Htt-positive aggregates in the R6/2 and N-171-82Q transgenic mouse models of HD118-120.”
§ Mitochondrial approaches for neuroprotection > Creatine
What the sources say
- Not checked yetcites [118] Andreassen OA 2001 Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease Neurobiol Dis 8 479 91 11447996 source
- Not checked yetcites [119] Dedeoglu A 2003 Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice J Neurochem 85 1359 67 12787055 PMC2866522 source
- Not checked yetcites [120] Ferrante RJ 2000 Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J Neurosci 20 4389 97 10844007 PMC6772461 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that creatine produced protection against dopamine loss, as well as an attenuation of neuron loss in the SN of mice treated with MPTP.”
§ Mitochondrial approaches for neuroprotection > Creatine
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In this study, oral administration of CoQ10 in PD patients was well tolerated and resulted in significant, dose-dependent increases in plasma CoQ10 levels.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [159] Shults CW 1997 Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects Ann Neurol 42 261 4 9266740 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Both SS-31 and SS-20 also produce complete protection against MPTP neurotoxicity (Yang et al., unpublished findings).”
§ Mitochondrial approaches for neuroprotection > Mitochondrial targeted antioxidants/peptides
What the sources say
- Not checked yetcites Yang et al., unpublished findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“We found a significant reduction in CoQ10 levels in mitochondria isolated from platelets of PD patients, that directly correlated with a decrease in complex-I activity159.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [159] Shults CW 1997 Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects Ann Neurol 42 261 4 9266740 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It reduces t-butylhydroperoxide induced ROS generation, attenuates MPTP-induced nigrostriatal dopaminergic neurodegeneration and reduces 3-NP induced striatal lesions.”
§ Mitochondrial approaches for neuroprotection > Triterpenoids
What the sources say
- Not checked yetcites Yang et al., unpublished findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mitochondrial dysfunction due to oxidative stress, mitochondrial DNA deletions, pathological mutations, altered mitochondrial morphology and interaction of pathogenic proteins with mitochondria leads to neuronal demise.”
§ Mitochondrial approaches for neuroprotection > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Creatine was shown to reduce the UPDRS scores, and could not be rejected as futile based on the 30% DATATOP futility threshold.”
§ Mitochondrial approaches for neuroprotection > Creatine
What the sources say
- Not checked yetcites [130] 2006 A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease Neurology 66 664 71 16481597 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Oral administration of creatine produces a dose-dependent improvement in motor performance and extends survival in G93A transgenic ALS mice, where it protects against loss of both motor neurons and SN neurons114.”
§ Mitochondrial approaches for neuroprotection > Creatine
What the sources say
- Not checked yetcites [114] Klivenyi P 1999 Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis Nat Med 5 347 50 10086395 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There is ample evidence showing involvement of mitochondrial dysfunction in the pathogenesis of neurodegenerative disorders, therefore, one would predict that agents that alleviate mitochondrial dysfunction could be beneficial and exert neuroprotective effects.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Mitochondrial dysfunction is a valid therapeutic target for neurodegenerative diseases.
None of the sources cited for this claim have been checked yet.
In the paper
“Similarly, we and others, by using CoQ10 and remacemide (NMDA antagonist) combination therapy observed significantly improved motor performance and increased survival in the R6/2 and the N-171-82Q transgenic mouse models of HD151, 154.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [151] Ferrante RJ 2002 Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease J Neurosci 22 1592 9 11880489 PMC6758854 source
- Not checked yetcites [154] Schilling G 2001 Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model Neurosci Lett 315 149 53 11716985 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The combination therapy of CoQ10 and minocycline in R6/2 transgenic mouse model of HD resulted in a significantly increased amelioration of behavioral and neuropathological deficits, extended survival, improved rotarod performance and attenuated striatal neuron atrophy, as compared to either minocycline or CoQ10 alone153.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [153] Stack EC 2006 Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice Biochim Biophys Acta 1762 373 80 16364609 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A dose ranging and efficacy study of highdose coenzyme Q10 formulations in the R6/2 HD transgenic mice demonstrated that high-dose CoQ10 significantly extends survival, improves motor performance, grip strength and reduces brain atrophy in R6/2 HD mice, in a dose-dependent manner152.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [152] Smith KM 2006 Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice Biochim Biophys Acta 1762 616 26 16647250 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Subsequently, in two other clinical trials, idebenone was safe and tolerable up to 360 mg/day and slowed progression of cognitive deficits in patients with AD168, 169.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [168] Gutzmann H Hadler D 1998 Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study J Neural Transm Suppl 54 301 10 9850939 source
- Not checked yetcites [169] Gutzmann H 2002 Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study Pharmacopsychiatry 35 12 8 11819153 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Mitochondrial-targeted antioxidants including mitochondrial CoQ10 (MitoQ) and Szeto-Schiller peptide (SS-31) play an important role in modulating ROS induced mitochondrial permeability transition and cell death, and were found to be protective in several in vitro and in vivo models of ischemia, reperfusion injury and neurodegeneration173.”
§ Mitochondrial approaches for neuroprotection > Mitochondrial targeted antioxidants/peptides
What the sources say
- Not checked yetcites [173] Armstrong JS 2007 Mitochondria-Directed Therapeutics. Antioxid Redox Signal 18092938
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings strongly support the notion that creatine, CoQ10 and idebenone are promising neuroprotective agents in debilitating neurodegenerative disorders.”
§ Mitochondrial approaches for neuroprotection > CoQ10
boostedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Similarly, a novel peptide antioxidant (SS-31) targeted to the inner mitochondrial membrane prevents apoptosis, necrosis, oxidative stress and inhibition of the mitochondrial electron transport chain176.”
§ Mitochondrial approaches for neuroprotection > Mitochondrial targeted antioxidants/peptides
What the sources say
- Not checked yetcites [176] Szeto HH 2007 Mitochondria-Targeted Cytoprotective Peptides for Ischemia-Reperfusion Injury Antioxid Redox Signal 17999629
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“SS-31 protects neuronal cells against tert-butyl-hydroperoxide (tBHP) induced mitochondrial depolarization and apoptotic cell death by reducing intracellular ROS, decreasing markers of apoptotic cell death and caspase activity177.”
§ Mitochondrial approaches for neuroprotection > Mitochondrial targeted antioxidants/peptides
What the sources say
- Not checked yetcites [177] Zhao K 2005 Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines Biochem Pharmacol 70 1796 806 16216225 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This trial was powered to be able to determine a 40% attenuation of total functional capacity decline with 80% power.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [155] 2001 A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease Neurology 57 397 404 11502903 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“MitoQ reduces ROS formation and preserves mitochondrial function after glutathione depletion, even in the cells lacking mitochondrial DNA175.”
§ Mitochondrial approaches for neuroprotection > Mitochondrial targeted antioxidants/peptides
What the sources say
- Not checked yetcites [175] Lu C 2007 Is Antioxidant Potential of the Mitochondrial Targeted Ubiquinone Derivative MitoQ Conserved in Cells Lacking mtDNA? Antioxid Redox Signal 17999633
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“MitoQ is a derivative of CoQ10 conjugated to triphenylalkylphosphonium ions, which promotes uptake into mitochondria, where it can combat ROS originating in mitochondria174.”
§ Mitochondrial approaches for neuroprotection > Mitochondrial targeted antioxidants/peptides
What the sources say
- Not checked yetcites [174] Tauskela JS 2007 MitoQ--a mitochondria-targeted antioxidant IDrugs 10 399 412 17642004
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The ratio of reduced to oxidized CoQ10 is significantly reduced in the platelets and cerebrospinal fluid (CSF) of PD patients156, 157 and in plasma of ALS patients158.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [156] Gotz ME 2000 Altered redox state of platelet coenzyme Q10 in Parkinson's disease J Neural Transm 107 41 8 10809402 source
- Not checked yetcites [157] Isobe C 2007 Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease J Clin Neurosci 14 340 3 16647853 source
- Not checked yetcites [158] Sohmiya M 2005 An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients J Neurol Sci 228 49 53 15607210 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“CoQ10 was safe and well tolerated at dosages of up to 1200 mg/day and a statistically significant dose-dependent reduction in UPDRS score was evident in subjects assigned to CoQ10 compared to those assigned to placebo.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
- Not checked yetcites [160] Shults CW 2002 Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline Arch Neurol 59 1541 50 12374491 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, plasma CoQ10 levels reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage in PD, HD or ALS patients161, 162.”
§ Mitochondrial approaches for neuroprotection > CoQ10
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“SS-31 also prevents Ca2+ induced cytochrome c release and inhibits 3-NP-induced activation of the MPT pore and mitochondrial depolarization in isolated mitochondria178.”
§ Mitochondrial approaches for neuroprotection > Mitochondrial targeted antioxidants/peptides
What the sources say
- Not checked yetcites [178] Zhao K 2004 Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury J Biol Chem 279 34682 90 15178689 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Following activation by TP, Nrf2 dissociates from Keap1, translocates to the nucleus, and binds to the ARE promoter sequences, leading to coordinated induction of a battery of cytoprotective genes including antioxidant and anti-inflammatory genes182.”
§ Mitochondrial approaches for neuroprotection > Triterpenoids
What the sources say
- Not checked yetcites [182] Lee JM 2005 Nrf2, a multi-organ protector? Faseb J 19 1061 6 15985529 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These studies suggest a potential neuroprotective effect of triterpenoids in cell and animal models of neurodegenerative disorders, and these compounds hold great promise as therapeutic agents for these disorders.”
§ Mitochondrial approaches for neuroprotection > Triterpenoids
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the Nrf2 knockout (Nrf2−/−) mice, injection of the mitochondrial complex-II inhibitor 3-NP causes increased motor deficits and striatal lesions as compared to the Nrf2+/+ mice, and these toxic effects of 3-NP were protected by adenoviral mediated over expression of Nrf2185.”
§ Mitochondrial approaches for neuroprotection > Triterpenoids
What the sources say
- Not checked yetcites [185] Shih AY 2005 Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo J Biol Chem 280 22925 36 15840590 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Sirtuin activation improves mitochondrial function, extends lifespan, and promotes longevity in various species including yeast193.”
§ Mitochondrial approaches for neuroprotection > PGC-1α and Sirtuins (Sir2)
What the sources say
- Not checked yetcites [193] Dali-Youcef N 2007 Sirtuins: the ‘magnificent seven’, function, metabolism and longevity Ann Med 39 335 45 17701476 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Synthetic TP compounds are potent inducers of the antioxidant response element (ARE)–Nrf2–Keap1 signaling pathway and are useful in a variety of the cancers including leukemia, multiple myeloma, osteosarcoma, breast and lung cancer181.”
§ Mitochondrial approaches for neuroprotection > Triterpenoids
What the sources say
- Not checked yetcites [181] Liby KT Yore MM Sporn MB 2007 Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer Nat Rev Cancer 7 357 69 17446857 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Synthetic triterpenoids (TP), analogues of oleanolic acid, are powerful inhibitors of oxidative stress and cellular inflammatory processes, and thus may be neuroprotective in neurodegeneration.”
§ Mitochondrial approaches for neuroprotection > Triterpenoids
What the sources say
- Not checked yetcites [181] Liby KT Yore MM Sporn MB 2007 Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer Nat Rev Cancer 7 357 69 17446857 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Additionally, the Nrf2 activator tertbutylhydroquinone, has attenuated 3-NP toxicity in Nrf2+/+ mice, but not in Nrf2−/− mice185.”
§ Mitochondrial approaches for neuroprotection > Triterpenoids
What the sources say
- Not checked yetcites [185] Shih AY 2005 Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo J Biol Chem 280 22925 36 15840590 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Neuronal cultures derived from the Nrf2 knockout mice show increased susceptibility to oxidative stress, as well as damage produced by mitochondrial electron transport chain complex inhibitors such as MPP+ and rotenone184.”
§ Mitochondrial approaches for neuroprotection > Triterpenoids
What the sources say
- Not checked yetcites [184] Lee JM 2003 NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons J Biol Chem 278 37948 56 12842875 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“These studies provide compelling evidence for a role of PGC-1α in the pathogenesis of neurodegenerative diseases, and thus it is a promising therapeutic target for neurodegenerative disorders2, 72.”
§ Mitochondrial approaches for neuroprotection > PGC-1α and Sirtuins (Sir2)
What the sources say
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Several agents, including creatine, CoQ10, MitoQ and idebenone are presently in clinical trials and show promising neuroprotective effects in these disorders.”
§ Mitochondrial approaches for neuroprotection > Conclusion and future perspective
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Identification of new therapeutic targets including PGC-1α and Sirtuins may provide new avenues for therapy of neurodegenerative diseases.”
§ Mitochondrial approaches for neuroprotection > Conclusion and future perspective
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“SIRT-1 activation by resveratrol increases survival of motor neurons from transgenic ALS mice and reduces learning impairment and neurodegeneration in AD mouse models by decreasing the acetylation of SIRT1 substrates PGC-1α and p53194.”
§ Mitochondrial approaches for neuroprotection > PGC-1α and Sirtuins (Sir2)
What the sources say
- Not checked yetcites [194] Kim D 2007 SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis Embo J 26 3169 79 17581637 PMC1914106 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Altogether, theses studies provide strong evidence for involvement of Sirtuins in neuroprotection and targeting of Sirtuins could be an attractive therapeutic approach in neurodegenerative disorders.”
§ Mitochondrial approaches for neuroprotection > PGC-1α and Sirtuins (Sir2)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Increased intracellular NAD+ concentration activates SIRT1 in brain following caloric restriction and this results in a reduction in amyloid pathology in a mouse model of Alzheimer disease197.”
§ Mitochondrial approaches for neuroprotection > PGC-1α and Sirtuins (Sir2)
What the sources say
- Not checked yetcites [197] Qin W 2006 Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction J Biol Chem 281 21745 54 16751189 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Similarly, resveratrol in another study improved motor function in mice which was accompanied by a decrease in PGC1α acetylation leading to increased activity and mitochondrial biogenesis196.”
§ Mitochondrial approaches for neuroprotection > PGC-1α and Sirtuins (Sir2)
What the sources say
- Not checked yetcites [196] Lagouge M 2006 Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha Cell 127 1109 22 17112576 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, therapeutic agents having the ability to target mitochondria and reduce mitochondrial dysfunction hold great promise for therapeutic interventions.”
§ Mitochondrial approaches for neuroprotection > Conclusion and future perspective
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
The paper relies on this without support.
Animal model results for neuroprotective agents predict clinical efficacy in human neurodegenerative diseases.
“The success of creatine in experimental studies led to clinical trials in neurodegenerative diseases including PD, HD and ALS.”
The paper relies on this without support.
Mitochondrial dysfunction is a valid therapeutic target for neurodegenerative diseases.
“There is ample evidence showing involvement of mitochondrial dysfunction in the pathogenesis of neurodegenerative disorders, therefore, one would predict that agents that alleviate mitochondrial dysfunction could be beneficial and exert neuroprotective effects.”
The paper relies on this without support.
Neuroprotective effects observed in animal models of neurodegenerative diseases predict neuroprotective efficacy in human patients.
“On the basis of results from animal studies, we and others initiated several clinical trials of CoQ10 in neurodegenerative disorders.”
The paper relies on this without support.
Plasma CoQ10 levels are a valid basis for selecting the dose for phase III clinical trials in HD.
“This dose was chosen based on the studies of plasma CoQ10 concentrations discussed above.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, CoQ10 offers neuroprotection in animal models of neurodegenerative diseases (e.g. Parkinson’s) [179, 180].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [179]
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
Self-citationRetractedBeckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., & Freeman, B. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1620 · Cited by 7,029
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
Self-citationDauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis
Kluck, R. M., Bossy‐Wetzel, E., Green, D. R., & Newmeyer, D. D. (1997) · Science · doi:10.1126/science.275.5303.1132 · Cited by 4,715
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,770
Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion
Campuzano, V., Montermini, L., Moltò, M. D., Pianese, L., Cossée, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A., et al. (1996) · Science · doi:10.1126/science.271.5254.1423 · Cited by 2,786
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
The mitochondrial permeability transition
Zoratti, M., & Szabó, I. (1995) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(95)00003-a · Cited by 2,410
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233
Normal oxidative damage to mitochondrial and nuclear DNA is extensive.
Richter, C., Park, J. W., & Ames, B. N. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.17.6465 · Cited by 1,730
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Mitochondrial control of apoptosis
Kroemer, G., Zamzami, N., & Susín, S. A. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80014-x · Cited by 1,476
Wong, P. C., Pardo, C. A., Borchelt, D., Lee, M. K., Copeland, N. G., Jenkins, N. A., Sisodia, S. S., Cleveland, D. W., & Price, D. L. (1995) · Neuron · doi:10.1016/0896-6273(95)90259-7 · Cited by 1,439
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,434
Self-citationBruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., et al. (1997) · Neuron · doi:10.1016/s0896-6273(00)80272-x · Cited by 1,341
Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis
Rothstein, J. D., Martin, L. J., & Kuncl, R. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262204 · Cited by 1,197
Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation
Harris, R. C., Söderlund, K., & Hultman, E. (1992) · Clinical Science · doi:10.1042/cs0830367 · Cited by 1,168
Nitric Oxide Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity
Zhang, J., Dawson, V. L., Dawson, T. M., & Snyder, S. H. (1994) · Science · doi:10.1126/science.8080500 · Cited by 1,118
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J. C., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,112
Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074
Abnormalities of the electron transport chain in idiopathic parkinson's disease
Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061
Steffan, J. S., Kazantsev, A. G., Spasić-Bošković, O., Greenwald, M., Zhu, Y., Goehler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,057
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W. A., & Reed, J. C. (1993) · PubMed · Cited by 1,030
Beal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J., Storey, E., Srivastava, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04181.1993 · Cited by 1,026
Self-citationPoly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia
Eliasson, M. J. L., Sampei, K., Mandir, A. S., Hurn, P. D., Traystman, R. J., Bao, J., Pieper, A. A., Wang, Z., Dawson, T. M., Snyder, S. H., et al. (1997) · Nature Medicine · doi:10.1038/nm1097-1089 · Cited by 1,019
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia
Rötig, A., de Lonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., Munnich, A., & Rustin, P. (1997) · Nature Genetics · doi:10.1038/ng1097-215 · Cited by 991
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 962
Self-citationMitochondria take center stage in aging and neurodegeneration
Beal, M. F. (2005) · Annals of Neurology · doi:10.1002/ana.20624 · Cited by 957
Self-citationRegulation of Mitochondrial Iron Accumulation by Yfh1p, a Putative Homolog of Frataxin
Babcock, M., de Silva, D., Oaks, R., Davis-Kaplan, S., Jiralerspong, S., Montermini, L., Pandolfo, M., & Kaplan, J. (1997) · Science · doi:10.1126/science.276.5319.1709 · Cited by 921
Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., & Khrapko, K. (2006) · Nature Genetics · doi:10.1038/ng1778 · Cited by 896
Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Self-citationMitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Muscle creatine loading in men
Hultman, E., Soderlund, K., Timmons, J. A., Cederblad, G., & Greenhaff, P. L. (1996) · Journal of Applied Physiology · doi:10.1152/jappl.1996.81.1.232 · Cited by 822
Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis
Ferrante, R. J., Browne, S. E., Shinobu, L. A., Bowling, A. C., Baik, M. J., MacGarvey, U. M., Kowall, N. W., Brown, R. H., & Beal, M. F. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69052064.x · Cited by 808
Self-citationZhao, K., Zhao, G.-M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., & Szeto, H. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402999200 · Cited by 782
Mitochondrial Dysfunction Is a Primary Event in Glutamate Neurotoxicity
Schinder, A. F., Olson, E. C., Spitzer, N. C., & Montal, M. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-19-06125.1996 · Cited by 770
Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite
Beckman, J. S., Ischiropoulos, H., Zhu, L., van der Woerd, M., Smith, C. D. L., Chen, J., Harrison, J. G., Martin, J. C., & Tsai, M. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90432-v · Cited by 768
Speakman, J. R., Talbot, D. A., Selman, C., Snart, S., McLaren, J. S., Redman, P., Krol, E., Jackson, D. M., Johnson, M. S., & Brand, M. D. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00097.x · Cited by 761
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Thomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Self-citationSIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling
Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.-F., Kwon, H., Yi, S., Mucke, L., & Gan, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509329200 · Cited by 740
Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease
Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., Stern, D., McKhann, G., & Du Yan, S. (2005) · The FASEB Journal · doi:10.1096/fj.05-3735fje · Cited by 738
α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress
Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E. M., Sisk, A., Mallory, M. E., Wong, J., Takenouchi, T., Hashimoto, M., & Masliah, E. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64553-1 · Cited by 737
Ripps, M. E., Huntley, G. W., Hof, P. R., Morrison, J., & Gordon, J. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.689 · Cited by 725
Kong, J., & Xu, Z. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03241.1998 · Cited by 723
Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease
Dunah, A. W., Jeong, H., Griffin, A. M., Kim, Y., Standaert, D. G., Hersch, S. M., Mouradian, M. M., Young, A. B., Tanese, N., & Krainc, D. (2002) · Science · doi:10.1126/science.1072613 · Cited by 708
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Marzo, I., Brenner, C., Zamzami, N., Susín, S. A., Beutner, G., Brdiczka, D. G., Rémy, R., Xie, Z.-H., Reed, J. C., & Kroemer, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1261 · Cited by 684
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Self-citationGurney, M. E., Cutting, F. B., Zhai, P., Doble, A., Taylor, C. P., Andrus, P. K., & Hall, E. D. (1996) · Annals of Neurology · doi:10.1002/ana.410390203 · Cited by 647
Mattiazzi, M., D’Aurelio, M., Gajewski, C. D., Martushova, K., Kiaei, M., Beal, M. F., & Manfredi, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203065200 · Cited by 639
Self-citationOrigin and functional consequences of the complex I defect in Parkinson's disease
Swerdlow, R. H., Parks, J. K., Miller, S. W., Davis, R. E., Tuttle, J. B., Trimmer, P. A., Sheehan, J. P., Bennett, J. P., & Parker, W. D. (1996) · Annals of Neurology · doi:10.1002/ana.410400417 · Cited by 638
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637
Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagarajan, M., MacGrogan, D., Rodgers, J. T., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602909200 · Cited by 626
Ischemic Brain Injury is Mediated by the Activation of Poly(ADP-Ribose)Polymerase
Endres, M., Wang, Z., Namura, S., Waeber, C., & Moskowitz, M. A. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199711000-00002 · Cited by 622
Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., & Gibson, G. E. (2005) · Annals of Neurology · doi:10.1002/ana.20474 · Cited by 622
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605208103 · Cited by 605
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
Dauer, W. T., Kholodilov, N. G., Vila, M., Trillat, A., Goodchild, R. E., Larsen, K. E., Staal, R. G. W., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 595
White, R. J., & Reynolds, I. J. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-18-05688.1996 · Cited by 592
Anandatheerthavarada, H. K., Biswas, G., Robin, M.-A., & Avadhani, N. G. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207030 · Cited by 571
Weydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.004 · Cited by 562
Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557
Self-citationBrain cytochrome oxidase in Alzheimer's disease
Kish, S. J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L., Wilson, J. M., DiStefano, L. M., & Nobrega, J. N. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09439.x · Cited by 537
Transcriptional abnormalities in Huntington disease
Sugars, K. L., & Rubinsztein, D. C. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00074-x · Cited by 535
Nrf2, a multi‐organ protector?
Lee, J., Li, J., Johnson, D. A., Stein, T. D., Kraft, A. D., Calkins, M. J., Jakel, R. J., & Johnson, J. A. (2005) · The FASEB Journal · doi:10.1096/fj.04-2591hyp · Cited by 532
Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis
Greenhaff, P. L., Bodin, K., Soderlund, K., & Hultman, E. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.266.5.e725 · Cited by 531
Toxicity of Familial ALS-Linked SOD1 Mutants from Selective Recruitment to Spinal Mitochondria
Liu, J., Lillo, C., Jonsson, P. A., Velde, C. V., Ward, C. M., Miller, T. M., Subramaniam, J. R., Rothstein, J. D., Marklund, S. L., Andersen, P. M., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.06.016 · Cited by 525
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522
Self-citationMutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro
Trushina, E., Dyer, R. B., Badger, J. D., Ure, D., Eide, L., Tran, D. D., Vrieze, B. T., Legendre-Guillemin, V., McPherson, P. S., Mandavilli, B. S., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.8195-8209.2004 · Cited by 520
Choo, Y. S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh162 · Cited by 515
Pasinelli, P., Belford, M. E., Lennon, N. J., Bacskai, B. J., Hyman, B. T., Trotti, D., & Brown, R. H. (2004) · Neuron · doi:10.1016/j.neuron.2004.06.021 · Cited by 506
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.-C., Yan, S.-D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318797 · Cited by 497
p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease
Bae, B.-I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., Ross, C. A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.005 · Cited by 495
Dykens, J. A. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63020584.x · Cited by 493
Brouillet, E., Hantraye, P., Ferrante, R. J., Dolan, R., Leroy‐Willig, A., Kowall, N. W., & Beal, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7105 · Cited by 485
Self-citation3-Nitropropionic Acid - Exogenous Animal Neurotoxin and Possible Human Striatal Toxin
Ludolph, A. C., He, F., Spencer, P. S., Hammerstad, J. P., & Sabri, M. I. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100032212 · Cited by 484
Jenkins, B. G., Koroshetz, W. J., Beal, M. F., & Rosen, B. R. (1993) · Neurology · doi:10.1212/wnl.43.12.2689 · Cited by 479
Self-citationStudies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin
Koutníková, H., Campuzano, V., Foury, F., Dollé, P., Cazzalini, O., & Koenig, M. (1997) · Nature Genetics · doi:10.1038/ng0897-345 · Cited by 473
Bioenergetic and Antioxidant Properties of Coenzyme Q10: Recent Developments
Littarru, G. P., & Tiano, L. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0052-y · Cited by 465
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease
Matthews, R. T., Yang, L., Jenkins, B. G., Ferrante, R. J., Rosen, B. R., Kaddurah-Daouk, R. F., & Beal, M. F. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00156.1998 · Cited by 431
Self-citationN-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking
Orr, A. L., Li, S., Wang, C.-E., Li, H., Wang, J., Rong, J., Xu, X., Mastroberardino, P. G., Greenamyre, J. T., & Li, X. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0106-08.2008 · Cited by 429
Vos, K. J. D., Chapman, A. L., Tennant, M. E., Manser, C., Tudor, E. L., Lau, K., Brownlees, J., Ackerley, S., Shaw, P. J., McLoughlin, D. M., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm226 · Cited by 420
Shih, A. Y., Li, P., & Murphy, T. H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4014-05.2005 · Cited by 413
Bernardi, P. (1996) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(96)00041-2 · Cited by 412
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Self-citationSirtuins: The ‘ magnificent seven ’, function, metabolism and longevity
Dali‐Youcef, N., Lagouge, M., Froelich, S., Koehl, C., Schoonjans, K., & Auwerx, J. (2007) · Annals of Medicine · doi:10.1080/07853890701408194 · Cited by 402
Floyd, R. A., Watson, J. J., & Wong, P. K. (1984) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(84)90042-3 · Cited by 397
Canto, M. C. D., & Gurney, M. E. (1994) · PubMed · Cited by 395
Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01592.2002 · Cited by 391
Self-citationCreatine and Cyclocreatine Attenuate MPTP Neurotoxicity
Matthews, R. T., Ferrante, R. J., Klivènyi, P., Yang, L., Klein, A., Mueller, G., Kaddurah-Daouk, R. F., & Beal, M. F. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7049 · Cited by 374
Self-citationAge-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid
Brouillet, E., Jenkins, B. G., Hyman, B. T., Ferrante, R. J., Kowall, N. W., Srivastava, R., Roy, D. S., Rosen, B. R., & Beal, M. F. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb05859.x · Cited by 367
High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain
Lin, M. T. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.2.133 · Cited by 366
Bosetti, F. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00314-1 · Cited by 348
Sherer, T., Richardson, J. R., Testa, C. M., Seo, B. B., Panov, A. V., Yagi, T., Matsuno‐Yagi, A., Miller, G. W., & Greenamyre, J. T. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04333.x · Cited by 348
BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE
MANN, V. M., COOPER, J. M., KRIGE, D., DANIEL, S. E., SCHAPIRA, A. H. V., & MARSDEN, C. D. (1992) · Brain · doi:10.1093/brain/115.2.333 · Cited by 346
Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue
Wilson, R. B., & Roof, D. M. (1997) · Nature Genetics · doi:10.1038/ng0897-352 · Cited by 345
Casey, A., Constantin-Teodosiu, D., Howell, S., Hultman, E., & Greenhaff, P. L. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.1.e31 · Cited by 343
Beutner, G., Rück, A., Riede, B., & Brdiczka, D. G. (1998) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(97)00175-2 · Cited by 342
Beutner, G., Rück, A., Riede, B., Welte, W., & Brdiczka, D. G. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)01092-7 · Cited by 337
Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326
Self-citationInvolvement of Free Radicals in Excitotoxicity In Vivo
Schulz, J. B., Henshaw, D. R., Siwek, D. F., Jenkins, B. G., Ferrante, R. J., Cipolloni, P. B., Kowall, N. W., Rosen, B. R., & Beal, M. F. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64052239.x · Cited by 322
Self-citationExpression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons
Ginsberg, S. D., Hemby, S. E., Lee, V. M. ‐., Eberwine, J. H., & Trojanowski, J. Q. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1 · Cited by 315
Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease
Gu, M., Cooper, J. A. D., Taanman, J., & Schapira, A. H. V. (1998) · Annals of Neurology · doi:10.1002/ana.410440207 · Cited by 313
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313
Self-citationA randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312
Lee, J.-M., Shih, A. Y., Murphy, T. H., & Johnson, J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305204200 · Cited by 308
Papucci, L., Schiavone, N., Witort, E. J., Donnini, M., Lapucci, A., Tempestini, A., Formigli, L., Zecchi‐Orlandini, S., Orlandini, G., Carella, G., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302297200 · Cited by 308
Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E. M., & Masliah, E. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00342-x · Cited by 301
Prospero, N. A. D., Baker, A., Jeffries, N. O., & Fischbeck, K. H. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70220-x · Cited by 300
Beal, M. F., Brouillet, E., Jenkins, B. G., Henshaw, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03633.x · Cited by 297
Self-citationGuimbal, C., & Kilimann, M. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52891-x · Cited by 294
Petit, P. X., Goubern, M., Diolez, P., Susín, S. A., Zamzami, N., & Kroemer, G. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00318-4 · Cited by 294
Green, A. L., Hultman, E., Macdonald, I. A., Sewell, D. A., & Greenhaff, P. L. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e821 · Cited by 294
Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L., Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0406 · Cited by 293
Self-citationHD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism
Seong, I. S., Ivanova, E. V., Lee, J., Choo, Y. S., Fossale, E., Anderson, M., Gusella, J. F., Laramie, J. M., Myers, R. H., Lesort, M. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi319 · Cited by 291
Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria
Velde, C. V., Miller, T. M., Cashman, N. R., & Cleveland, D. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712209105 · Cited by 287
Mitochondria-Targeted Cytoprotective Peptides for Ischemia–Reperfusion Injury
Szeto, H. H. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1892 · Cited by 274
Shih, A. Y., Imbeault, S., Barakauskas, V., Erb, H., Jiang, L., Li, P., & Murphy, T. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414635200 · Cited by 273
Damiano, M. G., Starkov, A. A., Petri, S., Kipiani, K., Kiaei, M., Mattiazzi, M., Beal, M. F., & Manfredi, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03619.x · Cited by 267
Self-citationMilakovic, T., & Johnson, G. V. W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504749200 · Cited by 259
Beal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256
Self-citationBeneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders
Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A. (2007) · Muscle & Nerve · doi:10.1002/mus.20688 · Cited by 255
Self-citationSteeghs, K., Benders, A. A. G. M., Oerlemans, F. T. J. J., HAAN, A. D., Heerschap, A., Ruitenbeek, W., Jost, C. R., van Deursen, J., Perryman, B., Pette, D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80186-5 · Cited by 252
Zhao, K., Luo, G., Giannelli, S., & Szeto, H. H. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.08.022 · Cited by 251
An analysis of the role of coenzyme Q in free radical generation and as an antioxidant
Beyer, R. E. (1992) · Biochemistry and Cell Biology · doi:10.1139/o92-061 · Cited by 251
McCarthy, S., Somayajulu, M., Sikorska, M., Borowy-Borowski, H., & Pandey, S. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.019 · Cited by 248
Benchoua, A., Trioulier, Y., Zala, D., Gaillard, M., Lefort, N., Dufour, N., Saudou, F., Elalouf, J., Hirsch, É. C., Hantraye, P., et al. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-07-0607 · Cited by 248
Calkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., & Johnson, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408487101 · Cited by 247
A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies
Tarnopolsky, M. A., Roy, B. D., & MacDonald, J. R. (1997) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199712)20:12 · Cited by 246
Burns, R. S., LeWitt, P. A., Ebert, M. H., Pakkenberg, H., & Kopin, I. J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505303122203 · Cited by 244
The role of creatine kinase in inhibition of mitochondrial permeability transition
O’Gorman, E., Beutner, G., Dolder, M., Koretsky, A. P., Brdiczka, D. G., & Wallimann, T. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01045-4 · Cited by 243
1 H NMR spectroscopy studies of Huntington's disease
Jenkins, B. G., Rosas, H. D., Chen, Y. I., Makabe, T., Myers, R. H., MacDonald, M. E., Rosen, B. R., Beal, M. F., & Koroshetz, W. J. (1998) · Neurology · doi:10.1212/wnl.50.5.1357 · Cited by 241
Self-citationThe Energetics of Huntington's Disease
Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240
Self-citationYamada, K., Tanaka, T., Han, D., Senzaki, K., Kameyama, T., & Nabeshima, T. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00408.x · Cited by 238
Bioenergetic approaches for neuroprotection in Parkinson's disease
Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236
Self-citationUCHINO, H., Elmér, E., UCHINO, K., Lindvall, O., & Siesjö, B. K. (1995) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1995.tb09999.x · Cited by 231
Brewer, G. J., & Wallimann, T. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741968.x · Cited by 230
Parker, W. D., Boyson, S. J., LUDER, A. S., & Parks, J. K. (1990) · Neurology · doi:10.1212/wnl.40.8.1231 · Cited by 230
Kristal, B. S., & Dubinsky, J. M. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69020524.x · Cited by 229
Experimental therapeutics in transgenic mouse models of Huntington's disease
Beal, M. F., & Ferrante, R. J. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1386 · Cited by 227
Self-citationChen, C., Wu, Y., Cheng, M., Liu, J., Lee, Y., Lee, P.-W., Soong, B., & Chiu, D. T.-Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.093 · Cited by 226
Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease
Shults, C. W., Flint Beal, M., Song, D., & Fontaine, D. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.003 · Cited by 223
Self-citationTrichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity
Gash, D. M., Rutland, K., Hudson, N. L., Sullivan, P. G., Bing, G., Cass, W. A., Pandya, J. D., Liu, M., Choi, D. Y., Hunter, R. L., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21288 · Cited by 223
Carrı̀, M. T., Ferri, A., Battistoni, A., Famhy, L., Gabbianelli, R., Poccia, F., & Rotilio, G. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01051-x · Cited by 221
Benecke, R., Strumper, P., & Weiss, H. (1993) · Brain · doi:10.1093/brain/116.6.1451 · Cited by 220
Mice lacking alpha-synuclein are resistant to mitochondrial toxins
Klivènyi, P., Siwek, D. F., Gardian, G., Yang, L., Starkov, A. A., Cléren, C., Ferrante, R. J., Kowall, N. W., Abeliovich, A., & Beal, M. F. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.018 · Cited by 216
Self-citationGuanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man.
Stöckler, S., Isbrandt, D., Hanefeld, F. A., Schmidt, B., & FIGURA, K. V. (1996) · PubMed Central · Cited by 213
Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial
Bender, A., Koch, W., Elstner, M., Schombacher, Y., Bender, J., Moeschl, M., Gekeler, F., Müller‐Myhsok, B., Gasser, T., Tatsch, K., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000238518.34389.12 · Cited by 205
Storch, A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.nct60005 · Cited by 205
Klivènyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y., & Beal, M. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02160.x · Cited by 201
Self-citationReduced platelet cytochrome c oxidase activity in Alzheimer's disease
Parker, W. D., Mahr, N., Filley, C. M., Parks, J. K., Hughes, D., Young, D. A., & Cullum, C. M. (1994) · Neurology · doi:10.1212/wnl.44.6.1086 · Cited by 199
Gordon, A., Hultman, E., Kaijser, L., Kristjánsson, S., Rolf, C., Nyquist, O., & Sylvén, C. (1995) · Cardiovascular Research · doi:10.1016/s0008-6363(95)00062-3 · Cited by 195
Liang, C., Wang, T. T., Luby‐Phelps, K., & German, D. C. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.015 · Cited by 190
Brouillet, M. (1995) · Medical Entomology and Zoology · Cited by 190
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Self-citationSomayajulu, M., McCarthy, S., Hung, M.-Y., Sikorska, M., Borowy‐Borowski, H., & Pandey, S. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.10.021 · Cited by 189
Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS
Zhang, W., Narayanan, M. V., & Friedlander, R. M. (2003) · Annals of Neurology · doi:10.1002/ana.10476 · Cited by 185
Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina
Sipilä, I., Rapola, J., Simell, O., & Vannas, A. (1981) · New England Journal of Medicine · doi:10.1056/nejm198104093041503 · Cited by 181
The role of mitochondria in inherited neurodegenerative diseases
Kwong, J. Q., Beal, M. F., & Manfredi, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03990.x · Cited by 180
Self-citationZhai, W., Jeong, H., Cui, L., Krainc, D., & Tjian, R. (2005) · Cell · doi:10.1016/j.cell.2005.10.030 · Cited by 179
Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
Feigin, A., Leenders, K. L., Moeller, J. R., Missimer, J. H., Kuenig, G., Spetsieris, P. G., Antonini, A., & Eidelberg, D. (2001) · PubMed · Cited by 178
Mitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175
Moon, Y., Lee, K. H., Park, J., Geum, D., & Kim, K. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03112.x · Cited by 174
Selective defect of in vivo glycolysis in early Huntington's disease striatum
Powers, W. J., Videen, T. O., Markham, J., McGee‐Minnich, L., Antenor‐Dorsey, J. A. V., Hershey, T. G., & Perlmutter, J. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609833104 · Cited by 174
Complex I Defect in muscle from patients with Huntington's disease
Arenas, J., Campos, Y., Ribacoba, R., Martín, M. A., Rubio‐Terres, C., Ablanedo, P., & Cabello, A. (1998) · Annals of Neurology · doi:10.1002/ana.410430321 · Cited by 174
Sasaki, S., & Iwata, M. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12314-4 · Cited by 173
Extracellular creatine regulates creatine transport in rat and human muscle cells.
Loike, J. D., Zalutsky, D. L., Kaback, E., Miranda, A. F., & Silverstein, S. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.3.807 · Cited by 171
Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169
Self-citationKumar, P., Padi, S. S., Naidu, P. S., & Kumar, A. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00014 · Cited by 167
Petri, S., Kiaei, M., Damiano, M., Hiller, A., Wille, E., Manfredi, G., Calingasan, N. Y., Szeto, H. H., & Beal, M. F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04018.x · Cited by 166
Self-citationFunctional Aspects of Creatine Kinase in Brain
Hemmer, W., & Wallimann, T. (1994) · Developmental Neuroscience · doi:10.1159/000111342 · Cited by 166
Gutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162
Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment
Valla, J., Schneider, L., Niedzielko, T., Coon, K. D., Caselli, R., Sabbagh, M. N., Ahern, G. L., Baxter, L., Alexander, G., Walker, D. G., et al. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.10.004 · Cited by 159
Therapeutic effects of coenzyme Q 10 (CoQ 10 ) and reduced CoQ 10 in the MPTP model of Parkinsonism
Cléren, C., Yang, L., Lorenzo, B. J., Calingasan, N. Y., Schomer, A. C., Sireci, A. N., Wille, E. J., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05097.x · Cited by 158
Self-citationNeuroprotective Effects of Inhibiting Poly(ADP-Ribose) Synthetase on Focal Cerebral Ischemia in Rats
Takahashi, K., Greenberg, J. H., Jackson, P., Maclin, K. M., & Zhang, J. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199711000-00001 · Cited by 158
Grafton, S. T., Mazziotta, J. C., Pahl, J. J., George-Hyslop, P. S., Haines, J. L., Gusella, J., Hoffman, J. M., Baxter, L. R., & Phelps, M. E. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530350075022 · Cited by 157
Pereira, C., Santos, M. S., & Oliveira, C. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0241 · Cited by 156
Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Thal, L. J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M. F., Zamrini, E., & Thomas, R. G. (2003) · Neurology · doi:10.1212/01.wnl.0000096376.03678.c1 · Cited by 156
Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease
Luoma, P. T., Eerola, J., Ahola, S., Hakonen, A. H., Hellström, O., Kivistö, K. T., Tienari, P. J., & Suomalainen, A. (2007) · Neurology · doi:10.1212/01.wnl.0000276955.23735.eb · Cited by 154
Tolerance of high‐dose (3,000 mg/day) coenzyme Q10 in ALS
Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M. F., Traynor, B., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187070.35365.d7 · Cited by 154
Self-citationSchilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02326-6 · Cited by 151
Increased Autophagic Degradation of Mitochondria in Alzheimer Disease
Moreira, P. I., Siedlak, S. L., Wang, X., Santos, M. S., Oliveira, C. R., Tabaton, M., Nunomura, A., Szweda, L. I., Aliev, G. M., Smith, M. A., et al. (2007) · Autophagy · doi:10.4161/auto.4872 · Cited by 150
Forsmark-Andrée, P., Lee, C.-P., Dallner, G., & Ernster, L. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00330-9 · Cited by 145
Potent mitochondria-targeted peptides reduce myocardial infarction in rats
Cho, J., Won, K., Wu, D., Soong, Y., Liu, S., Szeto, H. H., & Hong, M. K. (2007) · Coronary Artery Disease · doi:10.1097/01.mca.0000236285.71683.b6 · Cited by 144
Mutant Huntingtin Expression Induces Mitochondrial Calcium Handling Defects in Clonal Striatal Cells
Milakovic, T., Quintanilla, R. A., & Johnson, G. V. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603845200 · Cited by 142
Simon, D. K., Pulst, S. M., Sutton, J. P., Browne, S. E., Beal, M. F., & Johns, D. R. (1999) · Neurology · doi:10.1212/wnl.53.8.1787 · Cited by 141
Self-citationDecreased cAMP Response Element-mediated Transcription
Sugars, K. L., Brown, R. L., Cook, L. J., Swartz, J., & Rubinsztein, D. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310226200 · Cited by 139
Prophylactic Creatine Administration Mediates Neuroprotection in Cerebral Ischemia in Mice
Zhu, S., Li, M., Figueroa, B. E., Liu, A., Stavrovskaya, I. G., Pasinelli, P., Beal, M. F., Brown, R. H., Kristal, B. S., Ferrante, R. J., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1278-04.2004 · Cited by 138
Self-citationMetabolic Dysfunction in Familial, but Not Sporadic, Amyotrophic Lateral Sclerosis
Browne, S. E., Bowling, A. C., Baik, M. J., Gurney, M. E., Brown, R. H., & Beal, M. F. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71010281.x · Cited by 136
Self-citation
Research works printed but not linked: 3
- 10.1002/1531-8249(200011)48:5<723::aid-ana5>3.0.co;2-w · DOI
- 10.1111/j.1471-4159.2005.03112.x · DOI · Paper page
- 10.1002/ana.410420221 · DOI · Paper page
Cited by
Sorted by citations
Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Mitochondrial dysfunction in Parkinson's disease
Bose, A., & Beal, M. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13731 · Cited by 915
Self-citationRole of oxidative stress in depression
Bhatt, S., Nagappa, A. N., & Patil, C. R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.05.001 · Cited by 854
Leonard, B., & Maes, M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.005 · Cited by 805
Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease
Misrani, A., Tabassum, S., & Yang, L. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.617588 · Cited by 654
Metadata
- Authors
- Chaturvedi, R. K., & Beal, M. F.
- Affiliations
- Cornell University (US)
- Corresponding author
- Chaturvedi, Rajnish K.
- Beal, M. Flint
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2008-12
- Volume
- 1147
- Issue
- 1
- Pages
- 395-412
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- PMC
- PMC2605644
- OpenAlex
- W2157205154
- Cited by
- 294
- References
- 314
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 13 · 2023: 17 · 2022: 14 · 2021: 10 · 2020: 12 · 2019: 9 · 2018: 13 · 2017: 9 · 2016: 11 · 2015: 15 · 2014: 21 · 2013: 15 · 2012: 27
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of the New York Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01NS039258)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- mitochondrial dysfunction, neuroprotection, neurodegenerative diseases, oxidative stress, mitochondrial DNA deletions, creatine, coenzyme Q10, idebenone, synthetic triterpenoids, MitoQ, SS-31, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, PPARγ coactivator, sirtuins, mitochondria-targeted antioxidants
- MeSH terms
- Animals, Humans, Mitochondria, Neuroprotective Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
